Cover Image

A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database

ObjectiveThe purpose of this study is to investigate the drug safety of three Transthyretin (TTR) inhibitors in the real world using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.MethodsThis study extracted reports received by the FAERS database from...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuan Liu (Author), Hao Li (Author), Cheng Hu (Author), Li Tan (Author), Ping Yin (Author), Zhihao Li (Author), Shuangshan Zhou (Author), Li Su (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
by: Shangze Li, et al.
Published: (2024)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
by: Xiaogan Wang, et al.
Published: (2024)

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Zhiyuan Zhang, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024)

Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
by: Dan Liu, et al.
Published: (2024)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024)

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
by: Ruixue Liu, et al.
Published: (2024)

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021
by: Tingting Jiang, et al.
Published: (2024)

Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2024)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022)

Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Wen-Long Xie, et al.
Published: (2024)

Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
by: Maoxia Fan, et al.
Published: (2024)

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
by: Liyuan Liu
Published: (2024)

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
by: Yichun Shuai, et al.
Published: (2024)

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
by: Qiong Jie, et al.
Published: (2024)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
by: Zhi-Xuan Zhou, et al.
Published: (2022)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
by: Wei Wang, et al.
Published: (2023)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
by: Shuang Zhou, et al.
Published: (2022)

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Jinhua Chen, et al.
Published: (2024)

A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)
by: Huafei Tang, et al.
Published: (2024)

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
by: KaiLi Mao, et al.
Published: (2024)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
by: Tingting Jiang, et al.
Published: (2022)

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases
by: Mengmeng Peng, et al.
Published: (2024)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Dan Zhao, et al.
Published: (2024)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021)

Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system
by: Hongli Wang, et al.
Published: (2024)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
by: Renjun Yang, et al.
Published: (2022)

Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
by: Yuichi Uwai, et al.
Published: (2024)